Elementis/£ELM
1D1W1MYTD1Y5YMAX
Capital at risk
About Elementis
Elementis PLC, designated by the ticker ELM, is a global company specializing in the manufacture and sale of specialty chemicals. Established in 1844, the company primarily operates within the specialty chemicals industry, providing high-performance additives designed to enhance the capability of products across a diverse range of industries including personal care, coatings, talc, and chromium. Elementis is committed to delivering products that respond to the unmet needs and demands of their global clientele, focusing on quality, innovation, and sustainability.
- Ticker
- £ELM
- Sector
- Materials
- Primary listing
- LSE
- Employees
- 989
- Headquarters
- London, United Kingdom
- Website
- www.elementis.com
Elementis Metrics
BasicAdvanced
£959M
17.97
£0.09
0.92
£0.03
1.89%
Price and volume
Market cap
£959M
Beta
0.92
52-week high
£1.95
52-week low
£1.36
Average daily volume
1.2M
Dividend rate
£0.03
Financial strength
Current ratio
2.274
Quick ratio
1.375
Long term debt to equity
0.318
Total debt to equity
0.399
Dividend payout ratio (TTM)
33.47%
Interest coverage (TTM)
8.49%
Profitability
EBITDA (TTM)
118.59
Gross margin (TTM)
48.30%
Net profit margin (TTM)
11.86%
Operating margin (TTM)
22.15%
Effective tax rate (TTM)
30.12%
Revenue per employee (TTM)
£467,230
Management effectiveness
Return on assets (TTM)
7.66%
Return on equity (TTM)
10.67%
Valuation
Price to earnings (TTM)
17.967
Price to revenue (TTM)
2.091
Price to book
1.45
Price to tangible book (TTM)
13.01
Price to free cash flow (TTM)
35.801
Free cash flow yield (TTM)
2.79%
Free cash flow per share (TTM)
0.047
Dividend yield (TTM)
1.89%
Growth
Revenue change (TTM)
7.65%
Earnings per share change (TTM)
-198.87%
3-year revenue growth (CAGR)
-4.29%
10-year revenue growth (CAGR)
-0.41%
3-year earnings per share growth (CAGR)
18.61%
10-year earnings per share growth (CAGR)
-2.94%
10-year dividend per share growth (CAGR)
-6.11%
What the Analysts think about Elementis
Analyst ratings (Buy, Hold, Sell) for Elementis stock.
Analyst projections of the future price of Elementis stock.
Bulls say / Bears say
Elementis delivered mid-single digit organic revenue growth in H1 2026 with revenue up 4.7% to $318.2 million and adjusted operating profit rising 16.4% to $73.2 million, lifting adjusted margin to 23.0% and marking progress towards 2026 targets. (London Stock Exchange)
The sale of its pharmaceutical manufacturing business to Associated British Foods for an enterprise value of €34.3 million, completed on 2 June 2026, generated net proceeds of c.$35 million, improving group adjusted operating margin by 56 bps and sharpening focus on higher-value specialty additives. (London Stock Exchange)
Elementis launched a c.£25 million share buyback programme on 3 June 2026, funded by the pharma business sale proceeds, reflecting confidence in the balance sheet and delivering EPS accretion. (London Stock Exchange)
Coatings segment revenue declined 4.3% in FY2025, reflecting soft demand in all regions and indicating ongoing industrial market weakness. (Elementis)
Net debt stood at $185.4 million as of 31 December 2025, with net debt to EBITDA at 1.3×, underscoring elevated leverage and potential constraints on capital flexibility. (Elementis)
The Group reported a statutory loss of $45.5 million for the year ended 31 December 2025, driven by continued loss on discontinued operations, highlighting volatility from non-core divestments. (Elementis)
Data summarised monthly by Lightyear AI. Last updated on 26 Aug 2026.
Elementis Financial Performance
Revenues and expenses
Elementis Earnings Performance
Company profitability
Upcoming events
Funds containing Elementis
AllGBPEURUSD
Fund name | Fund size | £ELM weighting |
|---|---|---|
Vanguard FTSE 250£VMID | £1.6B | 0.32% |
iShares FTSE 250£MIDD | £661M | 0.31% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.08% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.08% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.